Physician profile
Nelson Velazquez
NPI 1730189747
$4,922.68
in general payments reported to CMS, 2019-2025
23 companies · $420 in 2025
The $420 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $975 · 2020: $529 · 2021: $611 · 2022: $554 · 2023: $952 · 2024: $881 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.63 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,872.89 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $709.96 | 2019-2025 | |
| Janssen Biotech, INC. | $613.35 | 2019-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $423.76 | 2019-2024 | Absorica Ld, Winlevi |
| Pfizer INC. | $319.40 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $181.82 | 2019-2023 | Libtayo |
| Dermavant Sciences, INC. | $114.26 | 2023-2024 | Vtama |
| Lilly USA, LLC | $83.05 | 2019-2021 | |
| Galderma Laboratories, L.P. | $79.30 | 2024 | |
| Dusa Pharmaceuticals, INC. | $77.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.85 | 2022-2025 | Spevigo |
| Ucb, INC. | $58.94 | 2020-2025 | Bimzelx |
| Leo Pharma INC. | $42.24 | 2022 | |
| Mission Pharmacal Company | $41.27 | 2019 | |
| Kerecis Limited | $37.98 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $34.62 | 2021 | |
| Convatec INC. | $33.10 | 2023 | |
| Biofrontera INC. | $27.02 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $24.83 | 2024 | Zoryve |
| Celgene Corporation | $24.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.10 | 2022 | |
| Incyte Corporation | $18.70 | 2025 | Opzelura |
| Genentech USA, INC. | $17.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Velazquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.